Public Employees Retirement System of Ohio Purchases Shares of 37,998 Alnylam Pharmaceuticals, Inc. $ALNY

Public Employees Retirement System of Ohio acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 37,998 shares of the biopharmaceutical company’s stock, valued at approximately $11,439,000.

A number of other institutional investors also recently modified their holdings of the company. iA Global Asset Management Inc. lifted its position in Alnylam Pharmaceuticals by 979.5% during the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after buying an additional 16,133 shares in the last quarter. SCS Capital Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $34,784,000. Hussman Strategic Advisors Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $2,505,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $50,773,000. Finally, Hsbc Holdings PLC raised its position in Alnylam Pharmaceuticals by 22.6% in the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock worth $35,675,000 after purchasing an additional 16,503 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $237.10 on Monday. The stock has a market cap of $31.73 billion, a P/E ratio of 44.07 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $495.55. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. The company has a fifty day simple moving average of $262.62 and a 200 day simple moving average of $293.54.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same period in the previous year, the company posted ($0.51) earnings per share. The company’s revenue for the quarter was up 66.9% on a year-over-year basis. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Analyst Ratings Changes

ALNY has been the subject of several research reports. Truist Financial lowered their target price on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Sanford C. Bernstein reissued an “outperform” rating and set a $376.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, August 25th. Raymond James Financial raised shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 target price on the stock in a research note on Monday, August 3rd. Oppenheimer dropped their price target on shares of Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Finally, HC Wainwright reduced their price objective on shares of Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $386.14.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.